[go: up one dir, main page]

MX2010002348A - Formulacion liquida de g-csf. - Google Patents

Formulacion liquida de g-csf.

Info

Publication number
MX2010002348A
MX2010002348A MX2010002348A MX2010002348A MX2010002348A MX 2010002348 A MX2010002348 A MX 2010002348A MX 2010002348 A MX2010002348 A MX 2010002348A MX 2010002348 A MX2010002348 A MX 2010002348A MX 2010002348 A MX2010002348 A MX 2010002348A
Authority
MX
Mexico
Prior art keywords
csf
liquid formulation
formulations
liquid formulations
kits
Prior art date
Application number
MX2010002348A
Other languages
English (en)
Inventor
Walter Hinderer
Heinz Lubenau
Original Assignee
Biogenerix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102007040932A external-priority patent/DE102007040932A1/de
Application filed by Biogenerix Ag filed Critical Biogenerix Ag
Publication of MX2010002348A publication Critical patent/MX2010002348A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Se describe formulaciones líquidas farmacéuticas de G-SF así como jeringas listas para usarse que contienen dichas formulaciones además de los equipos. Dichas formulaciones líquidas de G-CSF son estables durante un período extendido de tiempo y están substancialmente libres de auxiliar.
MX2010002348A 2007-08-27 2008-08-27 Formulacion liquida de g-csf. MX2010002348A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007040932A DE102007040932A1 (de) 2007-08-27 2007-08-27 Flüssigformulierung von G-CSF
EP07016763 2007-08-27
PCT/EP2008/007012 WO2009027076A1 (de) 2007-08-27 2008-08-27 Flüssigformulierung von g-csf

Publications (1)

Publication Number Publication Date
MX2010002348A true MX2010002348A (es) 2010-07-30

Family

ID=39745039

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002348A MX2010002348A (es) 2007-08-27 2008-08-27 Formulacion liquida de g-csf.

Country Status (20)

Country Link
US (3) US8562967B2 (es)
EP (2) EP2471510A1 (es)
JP (2) JP2010536906A (es)
KR (1) KR20100044261A (es)
CN (1) CN101795670A (es)
AU (1) AU2008291309B2 (es)
BR (1) BRPI0815280A2 (es)
CA (1) CA2697376C (es)
CY (1) CY1115815T1 (es)
DK (1) DK2076243T3 (es)
ES (1) ES2524454T3 (es)
HR (1) HRP20141217T1 (es)
IL (1) IL204118A (es)
MX (1) MX2010002348A (es)
NZ (1) NZ583999A (es)
PL (1) PL2076243T3 (es)
PT (1) PT2076243E (es)
SI (1) SI2076243T1 (es)
UA (1) UA100245C2 (es)
WO (1) WO2009027076A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
JP6524110B2 (ja) * 2014-03-20 2019-06-05 アルカームス ファーマ アイルランド リミテッド 注射速度が増大したアリピプラゾール調合物
US11896037B2 (en) 2016-08-03 2024-02-13 Temple University-Of The Commonwealth System Of Higher Education Microencapsulation of active agents
JP2019536761A (ja) * 2016-10-31 2019-12-19 フレゼニウス カービ ドイチュラント ゲーエムベーハー 液体医薬組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
WO1992016192A1 (en) * 1991-03-15 1992-10-01 Amgen Inc. Pulmonary administration of granulocyte colony stimulating factor
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
DE4242863A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
AU749815B2 (en) 1998-03-06 2002-07-04 Chugai Seiyaku Kabushiki Kaisha Protein-free preparations
DK0988861T3 (da) 1998-08-17 2004-04-19 Pfizer Prod Inc Stabiliserede proteinpræparater
ATE269716T1 (de) 2000-02-29 2004-07-15 Pfizer Prod Inc Stabilisierter granulozyten-kolonie- stimulierender faktor
AU2002345829A1 (en) 2002-06-24 2004-01-06 Dr. Reddy's Laboratories Ltd. Process for preparing g-csf
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
CN1878570B (zh) 2003-11-04 2010-10-06 力奇制药公司 包含粒细胞集落形成刺激因子的稳定的药物组合物
DE102006009437A1 (de) 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung

Also Published As

Publication number Publication date
WO2009027076A1 (de) 2009-03-05
US20100216698A1 (en) 2010-08-26
PT2076243E (pt) 2014-12-05
CA2697376C (en) 2016-07-19
NZ583999A (en) 2011-10-28
CA2697376A1 (en) 2009-03-05
JP2010536906A (ja) 2010-12-02
BRPI0815280A2 (pt) 2018-11-27
PL2076243T3 (pl) 2015-04-30
ES2524454T3 (es) 2014-12-09
KR20100044261A (ko) 2010-04-29
JP2015038111A (ja) 2015-02-26
US20150125420A1 (en) 2015-05-07
US8562967B2 (en) 2013-10-22
AU2008291309A1 (en) 2009-03-05
SI2076243T1 (sl) 2015-01-30
HRP20141217T1 (hr) 2015-02-27
UA100245C2 (uk) 2012-12-10
US9468685B2 (en) 2016-10-18
DK2076243T3 (da) 2015-01-05
AU2008291309B2 (en) 2013-10-17
CY1115815T1 (el) 2017-01-25
IL204118A (en) 2014-11-30
US20140030214A1 (en) 2014-01-30
US8946161B2 (en) 2015-02-03
EP2471510A1 (de) 2012-07-04
EP2076243A1 (de) 2009-07-08
EP2076243B9 (de) 2015-01-14
EP2076243B1 (de) 2014-10-01
CN101795670A (zh) 2010-08-04

Similar Documents

Publication Publication Date Title
ZA202106265B (en) Compositions and methods for inhibiting gene expression of lpa
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
EP4501352A3 (en) Compositions and methods for car t cell therapy
SG184222A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MX340463B (es) Formulaciones liquidas para un conjugado de g-csf de accion prolongada.
MX2015000813A (es) Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
PH12015501193A1 (en) Boronate ester compounds and pharmaceutical compositions thereof
EA028156B9 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
MX2010004613A (es) Composicion topica.
NZ718163A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
UA109144C2 (ru) Дезинфицирующий и антисептический препарат с пониженным содержанием йода
MY173582A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
UA105920C2 (uk) ПОХІДНІ СПОЛУК СТЕРОЇДАЛ[3,2-с]ПІРАЗОЛУ З ГЛЮКОКОРТИКОЇДНОЮ АКТИВНІСТЮ
MX2010002348A (es) Formulacion liquida de g-csf.
MX2012013607A (es) Polisacarido de las semillas de tamarindo para usarse en el tatamiento de enfermedades inflamatorias.
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
NZ599395A (en) Antisense formulation
MX2009012713A (es) Nuevos derivados de acido 3-fenil acrilico de receptores de tipo ppar, su metodo de preparacion y su uso en composiciones cosmeticas o farmaceuticas.
PH12015500070A1 (en) Pediatric oral liquid compositions containing nepadutant
IN2014DN10134A (es)

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: SUED-CHEMIE IP GMBH & CO. KG